Literature DB >> 23736701

Risk profile and clinical outcome of symptomatic subsegmental acute pulmonary embolism.

Paul L den Exter1, Josien van Es, Frederikus A Klok, Lucia J Kroft, Marieke J H A Kruip, Pieter Willem Kamphuisen, Harry R Büller, Menno V Huisman.   

Abstract

The clinical significance of subsegmental pulmonary embolism (SSPE) remains to be determined. This study aimed to investigate whether SSPE forms a distinct subset of thromboembolic disease compared with more proximally located pulmonary embolism (PE). We analyzed 3728 consecutive patients with clinically suspected PE. SSPE patients were contrasted to patients with more proximal PE and to patients in whom suspected PE was ruled out, in regards of the prevalence of thromboembolic risk factors and the 3-month risks of recurrent venous thromboembolism (VTE) and mortality. PE was confirmed in 748 patients, of whom 116 (16%) had SSPE; PE was ruled out in 2980 patients. No differences were seen in the prevalence of VTE risk factors, the 3-month risk of recurrent VTE (3.6% vs 2.5%; P = .42), and mortality (10.7% vs 6.5%; P = .17) between patients with SSPE and those with more proximal PE. When compared with patients without PE, aged >60 years, recent surgery, estrogen use, and male gender were found to be independent predictors for SSPE, and patients with SSPE were at an increased risk of VTE during follow-up (hazard ratio: 3.8; 95% CI: 1.3-11.1). This study indicates that patients with SSPE mimic those with more proximally located PE in regards to their risk profile and clinical outcome.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23736701     DOI: 10.1182/blood-2013-04-497545

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  29 in total

1.  Good clinical practice in pulmonary embolism diagnosis: where do we stand today?

Authors:  Marika Bajc; Lorenzo Maffioli; Massimo Miniati
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-02       Impact factor: 9.236

2.  Value of ventilation/perfusion SPECT for diagnosis of pulmonary embolism.

Authors:  Helmut Sinzinger; Robert Berent; Friedrich Kummer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-02-24       Impact factor: 9.236

Review 3.  Contrast-enhanced pulmonary MRA for the primary diagnosis of pulmonary embolism: current state of the art and future directions.

Authors:  Donald G Benson; Mark L Schiebler; Michael D Repplinger; Christopher J François; Thomas M Grist; Scott B Reeder; Scott K Nagle
Journal:  Br J Radiol       Date:  2017-04-12       Impact factor: 3.039

4.  Effect of medical thromboprophylaxis on mortality from pulmonary embolus and major bleedingy.

Authors:  J Alasdair Millar
Journal:  Australas Med J       Date:  2015-09-30

5.  Anticoagulant treatment for subsegmental pulmonary embolism.

Authors:  Hugo Hb Yoo; Vania Santos Nunes-Nogueira; Paulo J Fortes Villas Boas
Journal:  Cochrane Database Syst Rev       Date:  2020-02-07

Review 6.  Incidental venous thromboembolism: is anticoagulation indicated?

Authors:  Marcello Di Nisio; Marc Carrier
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

Review 7.  Prevention and Treatment of Venous Thromboembolism in Patients with Cancer: Focus on Drug Therapy.

Authors:  Nick van Es; Suzanne M Bleker; Ineke T Wilts; Ettore Porreca; Marcello Di Nisio
Journal:  Drugs       Date:  2016-03       Impact factor: 9.546

Review 8.  Symptomatic subsegmental pulmonary embolism: to treat or not to treat?

Authors:  Marc Carrier; Fredrikus A Klok
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

Review 9.  The role of computed tomography in the diagnosis of acute and chronic pulmonary embolism.

Authors:  Halil Doğan; Albert de Roos; Jacob Geleijins; Menno V Huisman; Lucia J M Kroft
Journal:  Diagn Interv Radiol       Date:  2015 Jul-Aug       Impact factor: 2.630

Review 10.  Epidemiology of venous thromboembolism.

Authors:  John A Heit
Journal:  Nat Rev Cardiol       Date:  2015-06-16       Impact factor: 32.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.